Department of Pediatrics, Division of Pediatric Clinical Pharmacology, Children's Hospital of Western Ontario, Western University, London, ON, Canada.
Department of Pediatrics, Division of Dermatology and Rheumatology, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON, Canada.
Br J Clin Pharmacol. 2024 Aug;90(8):1838-1855. doi: 10.1111/bcp.15490. Epub 2022 Aug 29.
Drug-induced skin disease or cutaneous adverse drug reactions (CADRs) are terms that encompass the clinical manifestations of the skin, mucosae and adnexa induced by a drug or its metabolites. The skin is the organ most frequently affected by drug reactions, which may affect up to 10% of hospitalized patients and occur in 1-3% of multimedicated patients. Most CADRs are mild or self-resolving conditions; however, 2-6.7% of could develop into potentially life-threatening conditions. CADRs represent a heterogeneous field and can be diagnostically challenging as they may potentially mimic any dermatosis. Currently, there are between 29-35 different cutaneous drug-reaction patterns reported ranging from mild dermatitis to an extensively burnt patient. The most frequently reported are maculopapular rash, urticaria/angioedema, fixed drug eruption and erythema multiforme. Less common but more severe patterns include erythroderma, drug reaction with eosinophilia and systemic symptoms, and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Almost any drug can induce a CADR, but antibiotics, nonsteroidal anti-inflammatory drugs and antiepileptics are the most frequently involved. Different mechanisms are involved in the pathogenesis of CADRs, although in some cases, these remain still unknown. CADRs could be classified in different ways: (i) type A (augmented) or type B (bizarre); (ii) immediate or delayed; (iii) immune-mediated or nonimmune-mediated; (iv) nonsevere or life-threatening; and (v) by their phenotype, including exanthematous, urticarial, pustular and blistering morphology. Recognizing a specific CADR will mostly depend on the ability of the physician to perform a detailed clinical examination, the proper description of the morphology of the skin lesions and supporting laboratory and/or skin biopsy findings.
药物性皮肤病或药物不良反应(CADR)是指药物或其代谢物引起的皮肤、黏膜和附属器的临床表现。皮肤是药物反应最常累及的器官,可能影响高达 10%的住院患者,在多药物治疗患者中发生 1-3%。大多数 CADR 是轻度或自限性的,但 2-6.7%的可能发展为潜在危及生命的情况。CADR 是一个异质性领域,可能具有挑战性,因为它们可能模拟任何皮肤病。目前,报告的不同皮肤药物反应模式有 29-35 种,从轻度皮炎到广泛烧伤患者。最常见的是斑丘疹、荨麻疹/血管性水肿、固定性药疹和多形红斑。不太常见但更严重的模式包括红皮病、药物反应伴嗜酸性粒细胞增多和全身症状以及史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症谱。几乎任何药物都可引起 CADR,但抗生素、非甾体抗炎药和抗癫痫药最常涉及。CADR 的发病机制涉及不同的机制,尽管在某些情况下,这些机制仍不清楚。CADR 可以通过多种方式分类:(i)A型(增强型)或 B 型(奇异型);(ii)即刻或延迟;(iii)免疫介导或非免疫介导;(iv)非严重或危及生命;和(v)根据其表型,包括出疹性、荨麻疹性、脓疱性和水疱性形态。识别特定的 CADR 主要取决于医生进行详细临床检查的能力、对皮肤损伤形态的正确描述以及支持实验室和/或皮肤活检结果。